HC Wainwright & Co. Maintains Buy on Emergent BioSolutions, Lowers Price Target to $12
Benzinga Newsdesk 7 months ago
NewsPrice TargetAnalyst Ratings
HC Wainwright & Co. analyst Raghuram Selvaraju maintains Emergent BioSolutions (NYSE:EBS) with a Buy and lowers the price target from $15 to $12.
HC Wainwright & Co. analyst Raghuram Selvaraju maintains Emergent BioSolutions (NYSE:EBS) with a Buy and lowers the price target from $15 to $12.